Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
2.210
+0.010 (0.45%)
Dec 24, 2024, 4:00 PM EST - Market closed
Lexaria Bioscience Employees
Lexaria Bioscience had 7 employees as of August 31, 2024. The number of employees increased by 2 or 40.00% compared to the previous year.
Employees
7
Change (1Y)
2
Growth (1Y)
40.00%
Revenue / Employee
$66,325
Profits / Employee
-$827,906
Market Cap
38.57M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Aug 31, 2024 | 7 | 2 | 40.00% |
| Aug 31, 2023 | 5 | -2 | -28.57% |
| Aug 31, 2022 | 7 | 1 | 16.67% |
| Aug 31, 2021 | 6 | 2 | 50.00% |
| Aug 31, 2020 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Enzo Biochem | 136 |
| Actinium Pharmaceuticals | 49 |
| Rallybio | 43 |
| SCYNEXIS | 29 |
| OneMedNet | 20 |
| Traws Pharma | 18 |
| CalciMedica | 12 |
| VYNE Therapeutics | 10 |
LEXX News
- 6 days ago - Lexaria's Registered GLP-1 Study #4 Begins Dosing - Accesswire
- 7 days ago - Lexaria Forms New Scientific Advisory Board - Accesswire
- 8 days ago - Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience - Accesswire
- 16 days ago - Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5 - Accesswire
- 4 weeks ago - Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs - Accesswire
- 4 weeks ago - Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled - Accesswire
- 5 weeks ago - ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study - Accesswire
- 5 weeks ago - Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study - Accesswire